SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq:LJPC - News) today announced that it will present data from its March 2007 interim antibody analysis on Riquent® (abetimus sodium), its drug candidate for systemic lupus erythematosus (“lupus” or “SLE”), at the annual meetings of the American Society of Nephrology on Saturday, Nov 3rd in San Francisco and the American College of Rheumatology on Nov 8th in Boston.
